molnupiravir, the oral pill, a game changer to pandemic?

陌路僻壤菲亚： 7.3% of 385 patients who received the antiviral oral pills  were either hospitalized or died from Covid-19, compared with 14.1% of the 377 patients who received a placebo

Molnupiravir would be simpler for patients -- no IV required -- and it works differently, by changing the SARS-CoV-2 virus to inhibit replication.

https://www.cnn.com/2021/10/02/health/antiviral-pill-covid-19-explainer/index.html

In comparison, monoclonal antibody phase III trial result: the phase III outcomes trial in high-risk non-hospitalised patients with COVID-19 met its primary endpoint, showing the investigational antibody cocktail of casirivimab and imdevimab significantly reduced the risk of hospitalisation or death by 70% (1,200 mg intravenously [IV]) and 71% (2,400 mg IV) compared to placebo.

https://www.roche.com/media/releases/med-cor-2021-03-23.htm?